Konstantinos Xynos
Net worth: 2 M $ as of 31/05/2026
Net worth: 2 M $ as of 31/05/2026
Konstantinos Xynos currently works at Replimune Group, Inc., as Chief Medical Officer from 2022.
Dr. Xynos also formerly worked at Deciphera Pharmaceuticals, Inc., as Vice President & Head-Global Medical Affairs from 2019 to 2021.
Dr. Xynos received his undergraduate degree in 1991 from the University of Illinois, Masters Business Admin degree in 2013 from the University of Strathclyde, doctorate degree in 1997 from Aristotle University of Thessaloniki, and doctorate degree in 2012 from National & Kapodistrian University of Athens.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 18/05/2026 | 235,662 ( 0.3% ) | 2 M $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01/12/2022 |
| Companies | Position | End |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aristotle University of Thessaloniki
Aristotle University of Thessaloniki Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National & Kapodistrian University of Athens
National & Kapodistrian University of Athens Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel drug candidates to improve the lives of cancer patients | Health Technology |
Select your edition
All financial news and data tailored to specific country editions